TY - JOUR
T1 - Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen
AU - Shah, Nirav N.
AU - Szabo, Aniko
AU - Saba, Raya
AU - Strelec, Lauren
AU - Kodali, Dheeraj
AU - Vaughn, John L.
AU - Esan, Olukemi
AU - Yang, David T.
AU - Mato, Anthony R.
AU - Kanate, Abraham S.
AU - Olteanu, Horatiu
AU - Hamadani, Mehdi
AU - Fenske, Timothy S.
AU - Kenkre, Vaishalee P.
AU - Svoboda, Jakub
AU - Cashen, Amanda F.
AU - Epperla, Narendranath
N1 - Funding Information:
N.N.S. reports equity ownership in Exelixis, Oncosec, and Geron; consulting for Jazz; advisory board for Kite and Juno; and research and travel support from Lentigen Technology. M.H. has received honoraria from Sanofi-Genzyme and Celgene; research funding from Takeda , Otsuka , Spectrum , Merck , and Astellas ; and consultancy for Medimmune, Cellerant, and Janssen. J.S. reports research funding from Celgene , Seattle Genetics , BMS , Merck , and Pharmacyclics ; and consulting from BMS and Seattle Genetics. The other authors have stated that they have no conflict of interest.
Funding Information:
N.N.S. reports equity ownership in Exelixis, Oncosec, and Geron; consulting for Jazz; advisory board for Kite and Juno; and research and travel support from Lentigen Technology. M.H. has received honoraria from Sanofi-Genzyme and Celgene; research funding from Takeda, Otsuka, Spectrum, Merck, and Astellas; and consultancy for Medimmune, Cellerant, and Janssen. J.S. reports research funding from Celgene, Seattle Genetics, BMS, Merck, and Pharmacyclics; and consulting from BMS and Seattle Genetics. The other authors have stated that they have no conflict of interest.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/2
Y1 - 2019/2
N2 - Grade 3A follicular lymphoma (FL) is a heterogenous disease with multiple frontline treatment regimens. We performed a multicenter retrospective analysis to evaluate the efficacy of various frontline regimens for grade 3A FL. Although anthracycline-based therapy was superior to the combination of chemotherapy with cyclophosphamide, vincristine, and prednisone for grade 3A FL, clinical outcomes, including survival, were similar compared to bendamustine-based treatment.
AB - Grade 3A follicular lymphoma (FL) is a heterogenous disease with multiple frontline treatment regimens. We performed a multicenter retrospective analysis to evaluate the efficacy of various frontline regimens for grade 3A FL. Although anthracycline-based therapy was superior to the combination of chemotherapy with cyclophosphamide, vincristine, and prednisone for grade 3A FL, clinical outcomes, including survival, were similar compared to bendamustine-based treatment.
KW - Chemotherapy
KW - Non-Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85058679508&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2018.11.010
DO - 10.1016/j.clml.2018.11.010
M3 - Article
C2 - 30581160
AN - SCOPUS:85058679508
SN - 2152-2650
VL - 19
SP - 95
EP - 102
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 2
ER -